Skip to content
DataLookout
Menu

NCT07947329

Treatments for Menstrual-Related Epilepsy

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Treatment efficacy in reducing perimenstrual seizure frequency
Timeframe: at the end of month 3

Secondary (1)

Treatment withdrawal rate

Arms and interventions

ClobazamActive comparator

One clobazam 10 mg tablet every 12 hours for 3 months on days -5 to +5 of the menstrual cycle.

AcetazolamideActive comparator

One acetazolamide 250 mg tablet every 12 hours for 3 months on days -5 to +5 of the menstrual cycle.

A 25% increase in the dose of the baseline antiseizure medicationActive comparator

A 25% increase in the dose of the baseline antiseizure medication for 3 months on days -5 to +5 of the menstrual cycle. If the patient is on polytherapy, the dose of one of the administered antiseizure medications that does not exceed the therapeutic range with a 25% increase will be escalated.

Drugs: Clobazam 10 MG Oral Tablet, Acetazolamide 250Mg Tab, Antiepileptic

Sites

1 site in 1 country

  • Mazandaran University of Medical SciencesSari, Mazandaran, Iran